Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/16/2026

Interpretation and Clinical Management of Positive Lyme IgM Tests

Pre‑test Probability and Clinical Context

  • Exposure history is the primary determinant of whether a positive IgM reflects true infection or a false‑positive result; patients without recent tick exposure in endemic regions have a markedly low pre‑test probability. 1
  • In non‑endemic areas (or without travel to endemic zones) the positive predictive value of a solitary IgM is ≈ 10 % (≈ 90 % false‑positives). 2
  • Even among patients presenting with arthritis, cranial neuropathies, or meningitis in low‑incidence regions, only about 0.7 % actually have Lyme disease. 1
  • Low‑pretest‑probability presentations (nonspecific fatigue, headache, myalgias, no objective findings, no exposure, or chronic symptoms lasting months) should not be evaluated with serology. [1][2]3

Timing of IgM Testing

  • IgM Western blot is only reliable within the first 4 weeks of symptom onset; after this period false‑positive rates rise sharply. 3
  • For illnesses persisting > 1 month, IgM results are clinically uninterpretable and IgG Western blot (≥ 5 of 10 specific bands) becomes the appropriate assay. 4

Two‑Tiered Testing Requirements

  • A positive IgM must be preceded by a positive or equivocal first‑tier assay (enzyme immunoassay or immunofluorescence assay). 5
  • Western blot interpretation is invalid without a positive first‑tier test; adherence to this rule markedly improves specificity. 6

IgM Western Blot Interpretation Criteria

  • A positive IgM Western blot requires at least two of the three specific bands: 24 kDa, 39 kDa, and 41 kDa. 3
  • The 41‑kDa band alone is not diagnostic; it cross‑reacts with other bacterial flagellar proteins and appears in ~ 43 % of healthy controls. 7
  • Interpreting fewer than the required bands leads to false‑positive diagnoses. 7

Clinical Scenarios Guiding Testing and Treatment

High Pre‑test Probability (Laboratory Testing Often Unnecessary)

  • Erythema migrans (EM) with compatible exposure warrants immediate treatment without serologic confirmation. 2
  • Typical EM occurring in an endemic area during the appropriate season also justifies prompt therapy without waiting for test results. 2

Intermediate Pre‑test Probability (Testing Helpful)

  • Acute neurologic (meningitis, facial palsy, radiculoneuritis) or cardiac (myocarditis, pericarditis with conduction abnormalities) manifestations in patients with plausible tick exposure should be evaluated with two‑tiered testing. (Citation omitted per instruction)
  • Nonspecific symptoms without objective findings, no tick exposure, or chronic symptom duration > 4 weeks should not be investigated with serology. [1][2]3

Treatment Recommendations

  • When objective clinical findings and appropriate exposure are present, initiate doxycycline 100 mg orally twice daily:
    • 10–14 days for early localized disease (EM). 3
    • 14–21 days for early disseminated disease (neurologic or cardiac involvement). 3
    • 28 days for Lyme arthritis. 3
  • Do not treat solely on the basis of a positive IgM; such results frequently represent false‑positives. 1
  • In the southern United States, consider Southern tick‑associated rash illness (STARI) as an alternative diagnosis for EM‑like rashes. 2

Testing Pitfalls and Best‑Practice Recommendations

  • Avoid using serology as a screening tool in asymptomatic individuals or those with nonspecific symptoms in non‑endemic areas. 1
  • Do not order non‑standard assays (e.g., urine antigen, CD57) that lack validation. (Citation omitted)
  • Ensure laboratories follow standard two‑tiered protocols: first‑tier EIA/IFA followed by Western blot only when the first tier is positive. 6
  • Do not diagnose “chronic Lyme disease” based on persistent serology; current evidence does not support this practice. 3

Practical Steps for Clinicians

  • Obtain a detailed tick‑exposure history (geography, season, duration). 1
  • Document objective findings (rash characteristics, neurologic deficits, cardiac abnormalities, joint swelling). 2
  • Verify that proper two‑tiered testing was performed and interpreted according to criteria. [1][3]
  • For symptom duration > 4 weeks, order an IgG Western blot and disregard the IgM result. 4
  • When Lyme disease is confirmed, assess for co‑infections (Babesia, Anaplasma, Ehrlichia) transmitted by Ixodes ticks. 3

Laboratory Testing Orders for Lyme Disease and Anaplasmosis

Introduction to Diagnostic Testing

  • The Infectious Diseases Society of America recommends a two-tiered serologic testing approach for patients with suspected Lyme disease, starting with an enzyme immunoassay (EIA) or immunofluorescence assay (IFA), with reflex Western immunoblot (both IgM and IgG) only if the first test is positive or equivocal 8

Lyme Disease Testing Orders

  • For patients with suspected Lyme disease, the Centers for Disease Control and Prevention (CDC) suggests ordering a two-tiered serologic testing approach, which has a high sensitivity for disseminated disease manifestations, such as meningitis, cranial neuropathies, carditis, and arthritis, with 88-100% sensitivity 9
  • The CDC recommends that for disease duration <6-8 weeks, IgM Western blot interpretation is valid; for longer duration, only IgG Western blot is clinically interpretable 8
  • IgG positivity requires ≥5 of 10 specific bands present, according to the CDC criteria 8
  • IgM positivity requires ≥2 of 3 specific bands present (plus positive/equivocal EIA), as per the CDC guidelines 8

Anaplasmosis Testing Orders

  • For suspected anaplasmosis, the Infectious Diseases Society of America recommends ordering serologic testing for Anaplasma phagocytophilum antibodies (IgM and IgG) by immunofluorescence assay or immunoblot 8
  • Consider adding "peripheral blood smear for morulae" as an adjunct test, though negative smears do not exclude the diagnosis, as suggested by the Infectious Diseases Society of America 8

Critical Pitfalls to Avoid

  • The American College of Physicians advises against ordering urine antigen tests or CD57 tests for Lyme disease, as these lack validation and are not recommended by any guideline 9
  • The Infectious Diseases Society of America recommends never retesting after treatment, as antibodies persist for months to years after successful treatment and do not indicate active infection 9
  • The American Academy of Family Physicians suggests never ordering testing in low-pretest-probability patients, as in non-endemic areas without tick exposure, positive predictive value drops to only 10%, and only 0.7% of patients with arthritis/neuropathy actually have Lyme disease 9

Lyme Disease Diagnostic Testing

Indications for Testing

  • The American College of Rheumatology recommends ordering testing for patients with acute neurologic manifestations, including meningitis, painful radiculoneuritis, mononeuropathy multiplex, acute cranial neuropathies, or spinal cord inflammation with epidemiologically plausible tick exposure 10, 11
  • The American College of Rheumatology recommends ordering testing for patients with acute myocarditis/pericarditis of unknown cause in endemic areas, particularly if presenting with dyspnea, palpitations, chest pain, syncope, or conduction abnormalities 10
  • Testing should not be ordered at the time of a tick bite, as antibodies are unlikely to be detectable and results would be misleading, according to the American Academy of Family Physicians 12
  • Routine testing is not recommended for patients with typical ALS, relapsing-remitting MS, Parkinson's disease, dementia, new-onset seizures, psychiatric illness, or developmental/behavioral disorders, as stated by the American College of Rheumatology 10, 11

Special Considerations

  • For disease duration <6-8 weeks, IgM Western blot is valid and requires ≥2 of 3 specific bands, and IgG Western blot requires ≥5 of 10 specific bands, according to the European Society of Clinical Microbiology and Infectious Diseases 13
  • In cases of suspected neuroborreliosis, the European Society of Clinical Microbiology and Infectious Diseases recommends ordering CSF analysis with cell count, differential, protein, and Lyme antibody index, along with a concurrent serum sample for comparison 13, 14
  • For suspected Lyme arthritis, consider synovial fluid or synovial biopsy for Lyme PCR, as suggested by the European Society of Clinical Microbiology and Infectious Diseases 13, 14

Timing‑Dependent Sensitivity of Lyme Disease Serologic Testing

Early Disease (< 7 days from symptom onset)

  • In patients evaluated within the first week of illness, serologic assays (EIA/IFA and Western blot) are typically negative, because antibody production has not yet occurred; clinical diagnosis therefore precedes laboratory confirmation. 15

Days 7–10 from Symptom Onset

  • Sensitivity of Lyme disease serologic tests begins to rise during the second week of illness, improving the likelihood of a positive result as the immune response matures. 15

≥ 14 days from Symptom Onset

  • After two weeks, immunofluorescence assay (IFA) sensitivity reaches 94 %–100 %, providing reliable detection of Borrelia‑specific antibodies. This performance is endorsed by the CDC’s 2006 recommendations. 15

REFERENCES

9

Lyme Disease Testing Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025